IL3 Fusion

CI-VAR-00001452Explore in graph →CIViC 5084

Curated evidence

Evidence by cancer (3 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–3 of 3 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
B Lymphoblastic Leukemia/Lymphoma with t(5;14)(q31.1;q32.3); IL3-IGH3
IGH::IL3 Fusion	(diagnostic)	Diagnostic	B	Supports Positive	3	accepted	EID12243 In this 2019 study, the authors included 8 patients with B-ALL presenting with t(5;14)(q31;q32) and reviewed another 16 patients from the literature. The median age at onset was 14.3 years (range of 4… (full text at CIViC) PMID 31921638 · Fournier et al., 2019 · Open in CIViC	civic
IGH::IL3 Fusion	(diagnostic)	Diagnostic	C	Supports Positive	4	accepted	EID12244 In this 2021 study the authors include four B-ALL cases with an IGH::IL3 gene fusion that initially were unable to be fully characterized by conventional methods. Patients' ages ranged from 6 to 19 ye… (full text at CIViC) PMID 33991782 · Guenzel et al., 2021 · Open in CIViC

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.